Ikarion Therapeutics
- Biotech or pharma, therapeutic R&D
Ikarion Therapeutics is Spain based and develops innovative treatments for osteoarthritis (OA), Its lead product IK-001 is a late pre-clinical stage First-in-Class disease modifying drug for Knee OA. It is a new drug product protected by a composition of matter IP application in national phases.
This innovative therapy uses a new MoA for OA which targets the underlying mechanisms of the disease. Activating PPARα prevents cartilage degradation by modulating key mechanisms such as senescence and autophagy in chondrocytes and cartilage. This results in reduced inflammation and improved structural function: slowing and potentially stopping cartilage degradation.
Administration by intraarticular injection (IA) of a novel biodegradable microsphere delivery technology for 2+month extended-release of the API with at least 3-month long-acting efficacy. It has shown to protect the joint structure and relieve pain in relevant animal models as well as in a retrospective study of a cohort database.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}